-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DZUQe5/Y1wL4DrGMooAViJtqtbNpbVlRR/Ag8iQfYECyvhgvy7x9ir6yjTAKYIp8
 itAUdzjenUBDOcIW6fvQxw==

<SEC-DOCUMENT>0001130319-06-000455.txt : 20060605
<SEC-HEADER>0001130319-06-000455.hdr.sgml : 20060605
<ACCEPTANCE-DATETIME>20060605121101
ACCESSION NUMBER:		0001130319-06-000455
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060605
FILED AS OF DATE:		20060605
DATE AS OF CHANGE:		20060605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06885319

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o31889e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of June 2006

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: June&nbsp;5, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o31889o3188900.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>Oncolytics Biotech Inc.&#146;s Research Collaborators Present<BR>
Positive REOLYSIN</B><SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> <B>Clinical Trial Data at ASCO Conference</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; June&nbsp;5, 2006 </B>- Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY) today
announced that two of its research collaborators presented positive interim and final results of
two Phase I clinical trials at poster sessions at the American Society of Clinical Oncology (ASCO)
Annual Meeting on June&nbsp;4, 2006 in Atlanta, Georgia. The data cover interim results of Oncolytics&#146;
Phase I systemic administration trial being conducted in the U.K. and final results of Oncolytics&#146;
Phase I recurrent malignant glioma trial conducted in Canada.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The results of these trials and previously completed and reported trials are consistent in
showing that REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> is well tolerated and can demonstrate activity in tumours when
delivered locally or systemically to patients with a wide variety of advanced cancers,&#148; said Dr.
Brad Thompson, President and CEO of Oncolytics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interim results of the Company&#146;s UK Phase I systemic administration clinical trial investigating
the use of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> to treat patients with advanced cancers indicated that
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> can be delivered systemically to various tumour types and cause virus-mediated
tumour responses. A total of 30 patients have been treated to date in the escalating frequency and
dosage portion of the trial to a maximum daily dose of 1x10<SUP style="font-size: 85%; vertical-align: text-top">11</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB>. To date
these 30 patients have received 65 courses of therapy, for a total of 284 daily treatments.
Patients have been entered into the study at the following dose levels (all TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB>):
1x10<SUP style="font-size: 85%; vertical-align: text-top">8 </SUP>for 1&nbsp;day, 1x10<SUP style="font-size: 85%; vertical-align: text-top">8 </SUP>for 3&nbsp;days, 1x10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>, 3x10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>,<SUP style="font-size: 85%; vertical-align: text-top">
</SUP>1x10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP>,<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>3x10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP>,<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>1x10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP> and 3x10<SUP style="font-size: 85%; vertical-align: text-top">10
</SUP>for five days, and<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>1x10<SUP style="font-size: 85%; vertical-align: text-top">11 </SUP>for three days.<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>A maximum
tolerated dose (MTD)&nbsp;was not reached and the treatment appears to have been well tolerated by the
patients.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Toxicities possibly related to REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> treatment in this trial have generally been
mild (grade 1 or 2) and have included chills, fever, headache, cough, runny nose, sore throat and
fatigue. Transient grade 3 toxicities include lymphopenia, neutropenia and troponin I. These
symptoms were more frequently observed from day two of treatment and usually lasted less than six
hours.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Of the cohorts whose patients have completed treatment (seven), anti-tumour activity was noted in
patients with colorectal, prostate, pancreatic, bladder, and NSCL cancer. Patients were assessed
with CTR scans, and where possible tumour marker assessment, and histopathology of tumour biopsies.
Two patients with colorectal cancer had tumour stabilization (one for three months, the other
classified as stable disease at six months) and had CEA tumour marker reduction of 27% and 60%
respectively. One patient with metastatic prostate cancer had stable disease at four months, had a
50% decrease in PSA, and had extensive product-induced necrosis with associated intratumoural viral
replication in metastatic lesions in the lymph nodes. One
patient with metastatic bladder cancer had stable disease at four months and had a minor tumour
response in a metastatic lesion in a lymph node (reduction from 2.5 to 1.9 cm). A patient with
pancreatic cancer and a patient with NSCL cancer had stable disease at four months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The primary objective of the Company&#146;s UK Phase I trial is to determine the MTD, dose limiting
toxicity (DLT), and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> when administered systemically to
patients. A secondary objective is to examine any evidence of anti-tumour activity. Eligible
patients include those who had been diagnosed with advanced or metastatic solid tumours that are
refractory (have not responded) to standard therapy or for which no curative standard therapy
exists.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In a second poster presentation, final results of a Canadian Phase I trial for recurrent
malignant glioma indicated that intratumoural administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> was well
tolerated by the patients and a maximum tolerated dose was not reached. A total of 12 patients
were treated with a single, intratumoural injection of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> at dosages of
1x10<SUP style="font-size: 85%; vertical-align: text-top">7</SUP>, 1x10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>, and 1x10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50 </SUB>in a delivery volume of
0.9 ml.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Toxicities possibly related to the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> treatment in this trial were generally mild
(grade 1 and 2) and included fever, headache and neutropenia. A transient grade 3 elevation in GGT
was noted. Three patients lived longer than one year, and one of these patients is still alive
approximately 45&nbsp;months post-treatment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The primary objective of the Company&#146;s Canadian Phase I trial was to determine the MTD, DLT, and
safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> when administered intratumourally to patients. A secondary
objective was to examine any evidence of anti-tumour activity. The study examined the use of a
single, intratumoural injection of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP>, delivered using imaging-guided surgery, in
patients with malignant glioma that had recurred despite other treatments, including surgery and
radiation therapy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Both ASCO posters can be found on the Oncolytics website at <U>www.oncolyticsbiotech.com</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation. For further information about Oncolytics,
please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company&#146;s expectations related to the interim results of the Phase I UK Systemic Administration
clinical trial investigating delivery of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> for advanced cancers, and the final
results of the Phase I Canadian trial for recurrent malignant glioma and the Company&#146;s belief as to
the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer therapeutic, involve known and unknown risks and
uncertainties, which could cause the Company&#146;s actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development projects, the efficacy of
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the success and timely completion of clinical studies
and trials, actual patient tolerance, the Company&#146;s ability to successfully commercialize
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>, uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the Company&#146;s quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements.</I>
</DIV>

<P align="left" style="font-size: 10pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Cathy Ward</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">210, 1167 Kensington Cr NW</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Calgary, Alberta T2N 1X7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Tel: 403.670.7377</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext. 226</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Fax: 403.283.0858</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>cathy.ward@oncolytics.ca</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">The Investor Relations Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RenMark Financial Communications</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Damian McIntosh</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Boidman</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">11 Stone Street, 3rd Floor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2080 Rene Levesque Blvd. W.</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">New York, NY 10004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montreal, PQ H3H&nbsp;1R6</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 514.939.3989</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 514.939.3717</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jboidman@renmarkfinancial.com</U></TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">-30-
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o31889o3188900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o31889o3188900.gif
M1TE&.#EA\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<```C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6&*S)FO,BQH\>/($.*I&B%2R!6UZ#-NG8-):M`
M5E:,G$FSILV;%U><O!:-):M9UEK):GEM:,N8.),J7<J4XXJ?UJX)5<FJ5*"K
MK++V1#DTD,RF8,.*9>I2ZDLK"E=88=6*Z,NQ<./*O;C6+5*':HG.8O5UKM^_
M@`4&*AJ-%=J).EE!.QJXL>.F.HEZS8D(Y;7#CS-K%CDX*^:+)#I?WDRZ=$71
MGSNB-LVZM4(K1:_U!0E;5K39KG.;7A'-=FJ0@7JSTDW<-"O;@6RBC,:EN//'
M=5D9L!F#55#<S[/#13D+^\A`0)-K_Q\_%C:TX3A70&M+OCW8K+-^T^PLWKU]
MFT];+ETQ%/W]_R/5M@=9O0%H8$@[R5=3(+X=Z"!'+GE7DX`(77450E5<)6%!
M5IR4U5D;"J26AUG!%"(`.L'$4(<:)L3B9RQ:*..,V*6H($$C?HB(B@DE]F&)
M=QWD$F2S1',(0L<)=U`7*-V(HF4E[E24@FNY]%(@B*C$&$)UU:=09WP=-)@L
M_@F4E5MHEO5;EU]"N6,I9X;)(906PJ>2EP.MT%*92J7$YT"L]+:507IL*29+
MDQ6TD9@1&O145][!EI5#@^V%6V>F,-3H0I+^*:)+7>"V*(<^U:@60OQ=@V=2
M/WD*P'&7;?\JD!4K*>C2JISVIU`I;>%J15</!;*8G*^R=*2F0YT(P*^J'O24
M2D]`Q."D$?$F"ZXW68:D5``P6%A?YG5QT%I[2812*T[6=IM!5O26:;"V\179
M6PT%VMV*[AXZBQ[56AF3LB(6B:U-K5CCJF+7"&:-I;,V>>AYU<ZR6(C\];:F
M;<?"N^=*`QL$E;*_&GD040`;Y.$U*[%RR+\]+EP*6&8A"50`@D5CL$RUR3=F
MQ\ZB;`T+"I5`V)KY1K23=3P7I-B]G!:-8ZD5=7AF3RT=(N&03/%G,)(J]<5%
M6WQ5T9;.\59[WF@]VA8?NQA/M),@$?TDVXIM>XQ2#!ZIM5S"0K;_5/)'[<XR
M8-_0S%8;*RQ8$XU\UA)+Z9ZO]0;-`>P6]:[1+:T2-S2R@&RYOI=W]&@KWNWT
MMT>!%&SK+$P/U&Y+M7*YE9-]H^WHN8",&VC&$.TQ%-P0R0WR[@>5<,AB5N<=
MJ#61HLSO4M:U,AWAV-7%^8WDGF=%3-N79`KC.\'T;XZ&DDIF]^@'>1`7O;T<
M?-<K?EYAH-=NK];V+1+D4O=JC=B?@GJB5E)4@#)H).1,D9(;[:2V$K>88F4N
M.HG$)N@N+FRH+E1CB0;GEA`]%(EW]9+8\)K5HT"8HBPN.42B1(25#4+)%"OL
M6^MN<@7D*$0%"R%!M4;E$!)H9`4X?!"._S2"EXRPK"&_@AA.`J"XS@GQB161
M"O-P4IND0?&*)@N*JT#R%)2<#HM8W)]R$`7&,CJD+AP<"2"$LL4\H4@D/.S1
M&P$FDY+%T5D$T:'H&/)%$?7Q4"B9B14*MCA-&>8D/`L$"&\G/L.DI4/7XM'\
MKK*]A5"R0R%*XPPI\I00P48\:UF(C3K4$5@YKB.#7)@5S\*BA7`A=(Y*(P!L
MEQ!9SJ]["Z%7O<1G!6C0#B-\<Y%A^!+*A!B`EJ)CB]\`=XV@6/%57M%;B/:P
M2!PY4D2R@`)#2,<0#=VQ(!=RR&4TLDG$G))#LE@6*P#1QA)<DXMG0B9B1/-,
M:'8OANSBF4ZZMY*'7[X*9+QTT@JN`(CN!1%)?3FG1)["*?2L0!#Z#.AK%+HM
ME.`3(FM16SW-R%&3$4557^RB%/W9T9(Z2F*R*-@[2\B=/?W1I"8USUY\PLKM
MF80M05G8>5X*TYY&IX!`*5A;;";%5I0";SU-:D5&I)*<`J4W>S&14J?JE!]J
8I`14S:I6M\K5KGKUJV`-JUC'NM6````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
